David Scadden

David Scadden

Directeur/Membre du Conseil chez AGIOS PHARMACEUTICALS, INC.

Fortune : 623 800 $ au 31/10/2026

73 ans
Health Technology
Consumer Services
Health Services

Profil

David T.
Scadden
is the founder of Fate Therapeutics, Inc., founded in 2007.
Dr. Scadden was the founder of The Massachusetts General Hospital, founded in 2003, where the title held was Director-Hematologic Malignancies Center.
Dr. Scadden is the founder of Harvard Stem Cell Institute, founded in 2004, holding the title of Director.
Dr. Scadden was the founder of Magenta Therapeutics, Inc., founded in 2015, where the title held was Independent Director.
Dr. Scadden is also the founder of Stratus Therapeutics, Inc.,The General Hospital Corp.,Clear Creek Bio, Inc...
Dr. Scadden currently holds the position of Chairman-Emeritus & Professor at Harvard University since 2006.
Dr. Scadden is Chairman-Emeritus & Professor at Harvard Medical School.
Dr. Scadden is an Independent Director at Agios Pharmaceuticals, Inc. since 2017.
Dr. Scadden is a Director at Lightning Biotherapeutics, Inc. Dr. Scadden is an Independent Director at Editas Medicine, Inc. since 2019.
Dr. Scadden is a Director at Red Oak Medicines, Inc. Dr. Scadden is a Director at Lifevault Bio.
Dr. Scadden is a Director at Sonata Therapeutics, Inc. Dr. Scadden is an Associate Member at Massachusetts Institute of Technology.
Dr. Scadden is a Member of the American Academy of Arts & Sciences.
Dr. Scadden is a Member of the National Academy of Medicine (United States).
Dr. Scadden is an Associate Member at The Broad Institute, Inc. Former positions include Director at The International Society for Stem Cell Research.
Dr. Scadden was Independent Director at Carisma Therapeutics, Inc. from 2024 to 2025.
Dr. Scadden was Member-Scientific Counselors Board at National Cancer Institute.
Dr. Scadden was Member-External Experts Board at National Heart, Lung & Blood Institute.
Education includes undergraduate degree from Bucknell University, doctorate degrees from Case Western Reserve University and the University of Lund.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
18/06/2026 20 419 ( 0,03 % ) 623 800 $ 31/10/2026
31/05/2025 0 ( -.--% ) - $ 31/10/2026
17/06/2026 0 ( -.--% ) - $ 31/10/2026

Postes actifs de David Scadden

SociétésPosteDébut
AGIOS PHARMACEUTICALS, INC. Directeur/Membre du Conseil 27/05/2017
EDITAS MEDICINE, INC. Directeur/Membre du Conseil 06/02/2019
Fondateur -
Fondateur 01/04/2004
Fondateur -
Directeur/Membre du Conseil -
Directeur/Membre du Conseil 01/01/2006
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ -

Anciens postes connus de David Scadden

SociétésPosteFin
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -
░░░░░░░░ ░░░░░░ ░░░░ ░░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -
░░░ ░░░░░░░░░░░░░ ░░░░░░░ ░░░ ░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ -
Voir l'expérience en détail de David Scadden

Formation de David Scadden

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

64

Relations au 1er degré

26

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées26

Health Technology

Consumer Services

Health Services

Finance

Consumer Services

Consumer Services

Miscellaneous

Consumer Services

Commercial Services

Commercial Services

Health Services

Health Technology

Government

Health Technology

Consumer Services

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Lightning Biotherapeutics, Inc.

Industrial Services

  1. Bourse
  2. Insiders
  3. David Scadden
🔇